Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Physiol Res ; 68(Suppl 1): S65-S74, 2019 11 22.
Article in English | MEDLINE | ID: mdl-31755292

ABSTRACT

Low back pain (LBP) represents an important subgroup of vertebrogenic pain with estimated prevalence around 80 %. Locally acting injectable collagen for topical application has recently extended the limited range of treatment options. The aim of the study was to evaluate the efficacy and safety of injectable collagen in patients with LBP. Patients suffering from LBP (< three months) were enrolled. They were administered either collagen 4 ml or trimecaine 1 % 4 ml in the form of subcutaneous paravertebral injections into eight pre-specified points (0.5 ml per each point) in the following schedule: two administrations in the first and second week, one in the third week. The pain intensity, Thomayer distance, Oswestry disability index, Lasseque test, quality of life, consumption of rescue medication and safety were evaluated. Exertional and rest pain, evaluated by a visual analogue scale, gradually decreased in both groups. Both treatments showed a statistically significant improvement in mobility and quality of life. The consumption of paracetamol as a rescue medication was significantly lower in patients treated with collagen than in the group treated with trimecaine (p=0.048). The analgesic efficacy of locally acting injectable collagen, as well as an analgesic sparing effect when compared to local anesthetics were demonstrated.


Subject(s)
Acute Pain/drug therapy , Collagen/administration & dosage , Low Back Pain/drug therapy , Trimecaine/administration & dosage , Adult , Aged , Analgesics/administration & dosage , Female , Hamamelis , Humans , Male , Middle Aged , Plant Extracts/administration & dosage , Plant Roots/chemistry , Prospective Studies , Single-Blind Method , Treatment Outcome
2.
Curr Med Chem ; 26(6): 1019-1026, 2019.
Article in English | MEDLINE | ID: mdl-29756567

ABSTRACT

Chronic low back pain (CLBP) syndrome represents one of the leading causes of long-term disability worldwide. The prevalence of CLBP has been rising significantly in relation to increasing average life expectancy. CLBP results from chronification of acute low back pain. There are many factors contributing to the CLBP crisis; common etiopathogenetic factors include e.g., functional blockage of intervertebral joints. The treatment of CLBP is complex. An important part of treatment consists of pain pharmacotherapy, for which several groups of drugs are used. The problem lies in the side effects of many of these traditionally used medications. Therefore, new and safer treatment methods are being sought. Innovative options for CLBP pharmacology include injections containing collagen, which can be combined with other traditionally used drugs, which helps reduce dosages and increase the overall safety of CLBP therapy.


Subject(s)
Analgesics/therapeutic use , Chronic Pain/drug therapy , Low Back Pain/drug therapy , Humans , Quality of Life
SELECTION OF CITATIONS
SEARCH DETAIL
...